Study on Regulation of LncRNA to Regulatory B Cells(Bregs) Through Notch Pathway in Patients With Thymoma and Autoimmune Diseases
Trial Snapshot
- Phase
- Not Applicable
- Status
- Withdrawn
- Locations
- 1
- Primary Endpoint
- The relationship between LncRNA and Notch2 signaling pathway
Study Overview
Brief Summary
Initially investigators will find LncRNA which to be able to affect Notch2 signaling pathway; then confirm the relationship between Notch2 and LncRNA, and analysis the regulation mode of LncRNA to Notch2 signaling pathway, and to observe the correlation between LncRNA and thymoma complicated with autoimmune diseases.
Detailed Description
- This study plans to research the correlation between Bregs and thymoma complicated with autoimmune diseases and the regulation the severity of the disease.
- Clarify different expression levels of Notch2 signaling pathway in thymoma complicated with autoimmune diseases, and the effect on Regulatory B Cells(Bregs).
- Find the effective regulation mode of Notch2 signaling pathway and the regulation of Bregs cell development and function in LncRNA.
Study Design
- Study Type
- Observational
- Observational Model
- Case Only
- Time Perspective
- Prospective
Eligibility Criteria
- Ages
- 18 Years to 65 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •(1) The patients with the diagnosis of mediastinal tumors (thymoma, thymic hyperplasia);
- •(2) The patients with the diagnosis of autoimmune diseases;
- •(3) Age of 18 years or older which expected to stay in ICU for≥5 days.
- •(4) APACHE II score > 15;
- •(5) The patients or authorized clients agree to participate in the clinical trial and sign the informed consent.
Exclusion Criteria
- •(1) the patients with circulatory, respiratory failure and major organ dysfunction after being endangered and transferred to ICU;
- •(2) patients with severe liver and renal dysfunction;
- •(3) pregnant or lactating women;
- •(4) patients who have not signed the informed consent;
- •(5) any factors that may be expected to increase the risk of patients or other factors that may interfere with the outcome of clinical trials.
Outcomes
Primary Outcomes
The relationship between LncRNA and Notch2 signaling pathway
Time Frame: 2016.10.01~2018.09.31-up to 24 months
Using of Real-Time Polymerase Chain Reaction(RT-PCR) and Western-Blot to find special LncRNA that can affect the Notch2 signaling pathway LncRNA's and Notch2 signaling pathway's gene and protein expression level Then, using of SiRNA to inhibit the expression of LncRNA or plasmid transfection to raise the expression of LncRNA, and observation of changes of Notch2 signaling pathway.
Secondary Outcomes
- The regulated effect of Notch2 signaling pathway to the development of Bregs and the cell function(2016.10.01~2018.09.31-up to 24 months)